Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation

Journal of Natural Products

Volumn 74, Issue 4, 2011, Pages 664-669

  Cuomo, John ^a   Appendino, Giovanni ^b   Dern, Adam S ^a   Schneider, Erik ^a   McKinnon, Toni P ^a   Brown, Mark J ^a   Togni, Stefano ^c   Dixon, Brian M ^a  

^a USANA Health Sciences Inc   (United States)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c INDENA S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; DRUG METABOLITE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG STABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN;

CHEMISTRY, PHARMACEUTICAL; CURCUMIN; HUMANS; LECITHINS; MOLECULAR STRUCTURE; REFERENCE STANDARDS;

EID: 79955411920     PISSN: 01633864     EISSN: 15206025     Source Type: Journal    
DOI: 10.1021/np1007262     Document Type: Article

References (46)

1. Keith, C. T.; Borisy, A. A.; Stockwell, B. R. Nat. Rev. Drug Discovery 2005, 4, 71-78
2. Sams-Dodd, F. Drug Discovery Today 2005, 10, 139-147
3. Morphy, R.; Kay, C.; Rankovic, Z. Drug Discovery Today 2004, 9, 641-651
4. Mencher, S. K.; Wang, L. G. BMC Clin. Pharmacol. 2005, 5, 3
5. Gœl, A.; Jhurani, S.; Aggarwal, B. B. Mol. Nutr. Food Res. 2008, 52, 1010-1030
6. Epstein, J.; Sanderson, I. R.; Macdonald, T. T. Br. J. Nutr. 2010, 103, 1545-1557
7. Aggarwal, B. B.; Sung, B. Trends Pharmacol. Sci. 2009, 30, 85-94
8. Anand, P.; Thomas, S. G.; Kunnumakkara, A. B.; Sundaram, C.; Harikumar, K. B.; Sung, B.; Tharakan, S. T.; Priyadarsini, I. K.; Rajasekharan, K. N.; Aggarwal, B. B. Biochem. Pharmacol. 2008, 76, 1590-1661
9. Bisht, S.; Maitra, A. Curr. Drug Discovery Technol. 2009, 192-199
10. Anand, P.; Kunnumakkara, A. B.; Newman, R. A.; Aggarwal, B. B. Mol. Pharmaceutics 2007, 4, 807-818
11. Lao, C. D.; Ruffin, M. T.; Normolle, D.; Heath, D. D.; Murray, S. I.; Bailey, J. M.; Boggs, M. E.; Crowell, J.; Rock, C. L.; Brenner, D. E. BMC Complement. Altern. Med. 2006, 6, 10
12. Wang, Y. J.; Pan, M.-H.; Cheng, A.-L.; Lin, L.-I.; Ho, Y.-S.; Hsieh, C.-Y.; Lin, J.-K. J. Pharm. Biomed. Anal. 1997, 15, 1867-1876
13. Vareed, S. K.; Kakarala, M.; Ruffin, M. T.; Crowell, J. A.; Normolle, D. P.; Djuric, Z.; Brenner, D. E. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 1411-1417 In this study, only one of the six participants who received a 12 g/day dosage of curcuminoid mixture had plasma levels of free curcumin that reached the detection threshold (50 ng/mL). In all the other volunteers and in the six participants who received a dosage of 10 g curcumin/day, only conjugates were detected. In a recent study, none of the five cancer patients who received a daily dosage of 8 g curcumin had detectable plasma concentrations of unconjugated curcumin. Kanai, M.; Yoshimura, K.; Asada, M.; Imaizumi, A.; Suzuki, C.; Matsumoto, S.; Nishimura, T.; Mori, Y.; Masui, Tl; Kawuguchi, Y.; Yanagihara, K.; Yazumi, S.; Chiba, T.; Aggarwal, B. B. Cancer Chemother. Pharmacol. 2010, in press.
14. See: http://www.bioperine.com/curcumin.html.
15. Burgos-Moròn, E.; Calderón-Montaño, J. M.; Robles, A.; López-Lázaro, M. Int. J. Cancer 2010, 126, 1771-1775
16. Mancuso, C.; Barone, E. Trends Pharmacol. Sci. 2009, 30, 333-334
17. Bhardawaj, R. K.; Glaeser, H.; Becquemont, L.; Klotz, U.; Gupta, S. K.; Fromm, M. F. J. Pharmacol. Exp. Ther. 2002, 302, 645-650
18. Srinivasan, K. Crit. Rev. Food Sci. Nutr. 2007, 47, 735-748
19. Volak, L. P.; Chirmai, S.; Cashman, J. R.; Court, M. H. Drug Metab. Dispos. 2008, 36, 1594-1605 No significant effect of curcumin on the expression of P450 or PgP was, however, reported. Graber-Maier, A.; Berger-Büter, K.; Aeschlimann, J.; Bittle, C.; Kreuter, M.; Drewe, J.; Gutmann, H. Planta Med. 2010, in press.
20. Price, R. J.; Scott, M. P.; Giddings, A. M.; Walters, D. G.; Stierum, R. H.; Meredith, C.; Lake, B. G. Xenobiotica 2008, 38, 574-586
21. For sake of clarity, throughout the text curcumin refers to monomolecular 1a, while the mixture of the three curcuminoids will be referred to as natural curcumin or curcuminoids.
22. Jeffrey, B.; Fritz, M.; Brender, J. F.; Smith, P. E. S.; Lee, D.-K.; Ramamoorthy, A. J. Am. Chem. Soc. 2010, 131, 4490-4498
23. Semalty, A.; Semalty, M.; Rawat, M. S.; Franceschi, F. Fitoterapia 2010, 81, 306-314
24. Giori, A.; Franceschi, F. Phospholipid complexes of curcumin having improved bioavailability. Eur. Pat. Appl. EP1837030, 2006.
25. Marczylo, T. H.; Vershoyle, R. D.; Cooke, D. N.; Morazzoni, P.; Steward, W. P.; Gescher, A. J. Cancer Chemother. Pharmacol. 2007, 60, 171-177
26. Jurenka, J. S. Altern. Med. Rev. 2009, 14, 141-153 A direct comparison between a clinical dosage of curcumin as Meriva and the same amount of uncomplexed curcumin was not possible because uncomplexed curcumin dœs not produce consistently detectable plasma concentrations in humans at dosages lower than 2 g. (8) On the other hand, comparison of Meriva with very high dosages of uncomplexed curcumin would be biased by saturation effects and by the nonlinearity of its absorption, (8) affording unrealistic values of improved absorption. The 1.8 g reference dosage is a compromise between detectability and clinical activity of uncomplexed curcumin. Satoskar, R. R.; Shah, S. J.; Shenoy, S. G. Int. J. Clin. Pharmacol. Ther. Toxicol. 1986, 24, 651-654
27. Kuptniratsaikul, V.; Thanakhumtorn, S.; Chinswangwatanakul, P.; Wattanamongkonsil, L.; Thamlikitkul, V. J. Compl. Altern. Med. 2009, 15, 891-897 It should be pointed out that the published clinical trials on curcumin are small, often nonrandomized, and essentially open-label and that some of them gave negative results, even with higher dosages (4 g/day) of curcumin than those we have used as reference (see ref 12).
28. Belcaro, G.; Cesarone, M. R.; Dugall, M.; Pellegrini, L.; Ledda, A.; Grossi, M. G.; Togni, S.; Appendino, G. Panminerva Med. 2010, 52 (Suppl. 1) 55S-62S
29. Allegri, P.; Mastromarino, A.; Neri, P. Clin. Opthalmol. 2010, 4, 41-46
30. Belcaro, G.; Cesarone, M. R.; Dugall, M.; Pellegrini, L.; Ledda, A.; Grossi, M. G.; Togni, S.; Appendino, G. Altern. Med. Rev. 2010, 15, 337-344
31. The rate of absorption of curcuminoids increased with the dosage, and the first time point (2 h) for demethoxycurcumin (1b) and bisdemethoxycurcumin (1c) at the high dosage of Meriva was also the peak concentration. It is, therefore, possible that the AUC of these compounds might, actually, be underestimated at this dosage, with the effect of lecithin formulation being overall higher than reported. We are grateful to one reviewer for bringing this issue to our attention. The effect of dosage on the rate of absorption is, undoubtedly, intriguing and well worth further investigation.
32. In the case of flax lignans, it is, however, the para -oxygenated function that is reductively removed by gut microorganisms. Lampe, J. W. J. Nutr. 2003, 133 (Suppl. 3) 956S-964S
33. Aura, A. M. Phytochem. Rev. 2008, 7, 407-429
34. Possemiers, S.; Bolca, S.; Verstraete, W.; Heyerick, A. Fitoterapia 2011, 82, 45-58
35. Crozier, A.; Jaganath, I. B.; Clifford, M. N. Nat. Prod. Rep. 2009, 26, 1001-1043
36. Zhang, L.; Wu, C.; Zhao, S.; Yuan, D.; Lian, G.; Wang, X.; Wang, L.; Yang, J. Int. Immunopharmacol. 2010, 10, 331-338
37. Luthra, P. M.; Kumar, R.; Prakash, A. Biochem. Biophys. Res. Commun. 2009, 384, 420-425
38. Ahmed, T.; Gilani, A. H. Pharmacol., Biochem. Behav. 2009, 91, 554-559
39. Yodkeere, S.; Chaiwangyen, W.; Garbisa, S.; Limtrakul, P. J. Nutr. Biochem. 2009, 20, 87-95
40. Zhang, L. J.; Wu, C. F.; Meng, X. L.; Yuan, D.; Cai, X. D.; Wang, Q. L.; Yang, J. Y. Neurosci. Lett. 2008, 447, 48-53
41. Interestingly, turmeric is mainly consumed in fatty dishes (Duke, J. A. CRC Handbook of Medicinal Spices; CRC Press: Boca Raton, FL, 2003; pp 137 - 144), potentially increasing the bioavailability of "dietary" curcumin.
42. Roycik, M. D.; Fang, X.; Sang, Q. X. Curr. Pharm. Des. 2009, 15, 1295-1308
43. Nakayama, S. K. Methods Enzymol. 2005, 400, 263-272
44. Fu, S.; Kurzrock, R. Cancer 2010, 116, 4670-4676
45. Helix pomatia β-glucuronidase has also sulfatase activity and is routinely used for the complete hydrolysis of phase-2 conjugates of phenolic compounds. Vœlkel, W.; Kiranoglu, M.; Fromme, H. Environ. Res. 2011, 111, 143-148
46. Liu, A.; Lou, H.; Zhao, L.; Fan, P. J. Pharm. Biomed. Anal. 2006, 40, 720-727